MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
bluebird bio EPS Ratio 2011-2026 | BLUE
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio bluebird bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.93 | -2.93 | -11.9 | -9.95 | -14.3 | -10.7 | -7.71 | -7.07 | -4.81 | -1.83 | -2.02 | -13.8 | -172 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.83 | -172 | -20 |
Quarterly EPS Ratio bluebird bio
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.98 | - | -0.31 | -0.42 | -7.23 | - | -0.8 | -0.58 | 0.18 | - | -0.94 | -1.36 | -1.66 | -2.14 | -3.16 | -3.58 | -3.07 | -3.01 | -2.94 | -0.36 | -3.64 | -4.04 | -3.73 | -3.55 | -2.99 | -2.72 | -2.73 | -2.91 | -2.31 | -2.52 | -1.73 | -1.73 | -1.68 | -1.88 | -2.07 | -1.59 | -1.52 | -1.29 | -1.18 | -1.57 | -0.76 | -0.67 | -0.61 | -0.06 | -0.44 | -0.34 | -0.26 | -2.13 | -19.9 | -12.5 | 1.15 | -23.2 | -28.5 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 | -28.5 | -3.4 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
0.38 | $ 2.56 | -6.41 % | $ 239 M |  Israel |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
-0.19 | $ 0.89 | 1.48 % | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 22.24 | -1.9 % | $ 3.69 B | USA |
 |
Evogene Ltd.
EVGN
|
-0.83 | $ 0.79 | -0.65 % | $ 27.9 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
-0.34 | $ 6.15 | -8.21 % | $ 176 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Galapagos NV
GLPG
|
-1.58 | $ 27.84 | -2.04 % | $ 2.69 B |  Belgium |
 |
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
ImmuCell Corporation
ICCC
|
-0.12 | $ 8.42 | 0.88 % | $ 76 M | USA |
 |
Avenue Therapeutics
ATXI
|
-0.93 | - | -52.27 % | $ 4.45 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
Innoviva
INVA
|
4.02 | $ 23.07 | -2.62 % | $ 1.55 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-0.66 | $ 1.49 | 6.33 % | $ 235 M | France |
 |
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 100.23 | -1.8 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
Jaguar Health
JAGX
|
-23 | $ 0.23 | -5.81 % | $ 536 K | USA |
 |
Inventiva S.A.
IVA
|
-1.27 | $ 4.91 | -2.0 % | $ 138 M | France |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.04 | -1.34 % | $ 432 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 22.36 | -3.99 % | $ 2.84 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
-2.03 | $ 26.71 | 38.8 % | $ 1.44 B | Britain |
 |
Kamada Ltd.
KMDA
|
-0.05 | $ 8.15 | - | $ 260 M | Israel |
 |
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.42 | -4.39 % | $ 378 M | Britain |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.95 | 1.2 % | $ 4.86 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B |  Cayman-islands |